Plain-English translation of NCT06863376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD) — a condition where fat builds up in the liver. The study will compare patients who receive standard care plus the medication to patients who receive standard care plus a placebo (a dummy pill) over 3 months. Researchers want to understand if this treatment is safe and whether it actually improves liver health.
Fatty liver disease is becoming increasingly common and can lead to serious complications if left untreated. Right now, lifestyle changes like diet and exercise are the main recommendations, but doctors need better medication options to help patients — especially those with more advanced disease. This trial explores whether this medication could be a helpful addition to standard treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the medication or a placebo, both alongside your regular treatment plan. Everyone in the study will take their assigned treatment twice daily for 3 months. During this time, you'll likely have follow-up visits to check your liver health and report any side effects or concerns.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Egypt
Phase
Testing effectiveness
Sponsor
Tanta University
Enrollment target
~46 participants
Started
March 2025
Primary completion
March 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.